Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + lamivudine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Peginterferon alfa-2a + lamivudine is a combination therapy used primarily for the treatment of chronic hepatitis B virus (HBV) infection. Peginterferon alfa-2a is a pegylated form of interferon alpha, an immunomodulatory cytokine that enhances the host immune response against viral infections by inducing antiviral proteins and modulating immune cell activity. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI) that inhibits HBV DNA polymerase, thereby suppressing viral replication. The combination has been studied in both HBeAg-positive and HBeAg-negative chronic hepatitis B patients, showing higher rates of virologic and serologic response compared to lamivudine monotherapy, though not significantly superior to peginterferon alfa-2a monotherapy in terms of sustained post-treatment response[1][2][3][5]. Adverse events are generally consistent with those known for interferon-based therapies, including flu-like symptoms and psychiatric effects.
- Brand names
- PegasysZeffixEpivir-HBV
- Other names
- peginterferon alfa-2a + lamivudine
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfa-2a + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + lamivudine.